



US 20100273181A1

(19) **United States**

(12) **Patent Application Publication**
Chapoteau et al.

(10) **Pub. No.: US 2010/0273181 A1**

(43) **Pub. Date: Oct. 28, 2010**

(54) **METHODS FOR THE DETECTION OF
GLYCATED HEMOGLOBIN**

(75) Inventors: **Eddy Chapoteau**, Brooklyn, NY
(US); **Richard Edwards**, Cold
Spring, NY (US); **Chester Swirski**,
Yorktown, NY (US); **Wolodymyr
Zazulak**, New Fairfield, CT (US)

Correspondence Address:
SIEMENS CORPORATION
INTELLECTUAL PROPERTY DEPARTMENT
170 WOOD AVENUE SOUTH
ISELIN, NJ 08830 (US)

(73) Assignee: **Siemens Healthcare Diagnostics
Inc.**, Tarrytown, NY (US)

(21) Appl. No.: **12/743,615**

(22) PCT Filed: **Nov. 18, 2008**

(86) PCT No.: **PCT/US08/83847**

§ 371 (c)(1),
(2), (4) Date: **May 19, 2010**

Related U.S. Application Data

(60) Provisional application No. 60/989,210, filed on Nov.
20, 2007.

Publication Classification

(51) **Int. Cl.**
C12Q 1/37 (2006.01)
G01N 33/53 (2006.01)
G01N 33/546 (2006.01)

(52) **U.S. Cl.** **435/7.1; 435/24**

(57) **ABSTRACT**

Particular aspects of the present invention relate to methods for detecting glycated hemoglobin in, for example, human whole blood, that are not affected by the presence of variation in amino acid sequence that can exist in hemoglobin β chains. The methods detect all glycated hemoglobin in a sample, regardless of the form of the hemoglobin that has been glycated, and thus detect glycated human Hemoglobin A, Hemoglobin S, and Hemoglobin C.




Figure 1




Figure 2





Figure 3



Slope	1.698
Intercept	-2.79
Sy.x	0.67
R	0.971
#obs	27

Level	X observed	Y observed	Y fitted	% bias	Set Limit
Min	5.8	6.5	6.7	19.9	
Mean	6.9	6.9	6.9	29.3	
Max	13.0	19.8	19.3	48.3	

Figure 4






Figure 5



Slope	1.333
Intercept	-1.37
Sy.x	0.52
R	0.973
#obs	26

Level	X observed	Y observed	Y fitted	% bias	Set Limit
Min	5.6	5.8	6.1	8.9	
Mean	8.9	7.9	7.8	13.5	
Max	13.0	16.0	16.0	22.8	

Figure 6



Slope	1.177
Intercept	-0.62
Sy.x	0.43
R	0.975
#obs	27

Level	X observed	Y observed	Y fitted	% bias	Set Limit
Min	5.6	5.7	6.0	6.6	
Mean	6.9	7.5	7.5	8.6	
Max	13.0	14.8	14.7	12.9	

Figure 7





Figure 8



Slope	1.019
Intercept	0.02
Sy.x	0.35
R	0.978
nobs	27

Level	X observed	Y observed	Y fitted	% bias	Set Limit
Min	5.6	5.8	5.7	2.2	
Mean	6.9	7.0	7.0	2.2	
Max	13.0	13.1	13.3	2.1	

Figure 9




Figure 10

METHODS FOR THE DETECTION OF GLYCATED HEMOGLOBIN

FIELD OF THE INVENTION

[0001] Particular aspects of the present invention relate to methods for detecting glycosylated human hemoglobin in, for example, human whole blood, that are not affected by the presence of hemoglobin variants in the blood.

BACKGROUND OF THE INVENTION

[0002] Hemoglobin present in red blood cells can be glycosylated by the non-enzymatic addition of a glucose molecule to the amino terminus of the β -chain of the hemoglobin. Once a hemoglobin molecule is glycosylated, it remains glycosylated, and an accumulation of glycosylated hemoglobin within a red cell reflects the average level of glucose to which the cell has been exposed during its life cycle. The level of glycosylated hemoglobin present in an individual's blood is thus proportional to the level of glucose in the blood, and is an indicator of the individual's mean daily blood glucose concentration over the previous four weeks to three months.

[0003] Numerous methods exist for determining the level of glycosylated hemoglobin in human blood, most of which involve calculating the relative amount of glycosylated hemoglobin A (HbA1c) present in the blood, due to the fact that hemoglobin A (HbA) is the major form of hemoglobin present in human blood. Techniques such as high performance liquid chromatography and immunoaffinity selection are used in such methods, which take advantage of physical and/or chemical properties of glycosylated hemoglobin A that distinguish it from other forms of hemoglobin present in the blood.

[0004] Variant forms of hemoglobin exist, however, such as hemoglobin S (HbS) and hemoglobin C (HbC), which differ from hemoglobin A at the amino acid residue at position six of the hemoglobin β -chain. The hemoglobin S and hemoglobin C forms of hemoglobin can be glycosylated, and glycosylated hemoglobin S and hemoglobin C have been shown to interfere with most of the current methods for quantitating glycosylated human hemoglobin, causing up to a 40% elevation in the results. A need therefore exists for methods for detecting glycosylated human hemoglobin that are not subject to interference caused by hemoglobin variants.

SUMMARY OF THE INVENTION

[0005] In certain embodiments, the invention relates to methods for detecting glycosylated human hemoglobin that comprise contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase, contacting the endopeptidase-treated sample with proline-specific endopeptidase, and detecting glycosylated β -chain amino-terminal pentapeptide of human hemoglobin.

[0006] In other embodiments, the invention relates to methods for detecting glycosylated human hemoglobin that comprise contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase either simultaneously with, prior to, or following contacting the sample with an agglutinator reagent, contacting the endopeptidase and agglutinator reagent-treated sample with proline-specific endopeptidase,

and detecting glycosylated β -chain amino-terminal pentapeptide of human hemoglobin with an agglutination inhibition immunoassay.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] FIG. 1 depicts the rate of agglutination of latex coated with mouse monoclonal anti-HbA1c antibody caused by various formulations of an agglutinator reagent (polyaspartamide-conjugated β -chain amino-terminal glycosylated sexapeptide of human hemoglobin) over a period of 14 days. The formulations contained the agglutinator reagent without both ethylenediamine tetraacetic acid (EDTA) and proline-specific endopeptidase, with EDTA only, and with both EDTA and proline-specific endopeptidase.

[0008] FIG. 2 depicts the rate of agglutination of latex coated with mouse monoclonal anti-HbA1c antibody caused by various formulations of an agglutinator reagent (polyaspartamide-conjugated β -chain amino-terminal glycosylated sexapeptide of human hemoglobin) over a period of 18 days. The formulations contained the agglutinator reagent and proline-specific endopeptidase with both EDTA and BSA, or with BSA only.

[0009] FIG. 3 depicts a correlation slope in which the percentage of glycosylated hemoglobin present in human whole blood samples containing hemoglobin S and hemoglobin C calculated using the ADVIA® 1650 HbA1c method is plotted against the percentage of glycosylated hemoglobin present in the samples calculated using the DCA® 2000 HbA1c assay.

[0010] FIG. 4 depicts a correlation slope in which the percentage of glycosylated hemoglobin determined to be present in human whole blood samples containing hemoglobin S and hemoglobin C that were reacted with an agglutinator reagent and 0.0 U/mL proline-specific endopeptidase using an ADVIA® 1650 instrument is plotted against the percentage of glycosylated hemoglobin present in the samples determined using the DCA® 2000 HbA1c assay.

[0011] FIG. 5 depicts a correlation slope in which the percentage of glycosylated hemoglobin determined to be present in human whole blood samples containing hemoglobin S and hemoglobin C that were reacted with an agglutinator reagent and 0.1 U/mL proline-specific endopeptidase using an ADVIA® 1650 instrument is plotted against the percentage of glycosylated hemoglobin present in the samples determined using the DCA® 2000 HbA1c assay.

[0012] FIG. 6 depicts a correlation slope in which the percentage of glycosylated hemoglobin determined to be present in human whole blood samples containing hemoglobin S and hemoglobin C that were reacted with an agglutinator reagent and 0.2 U/mL proline-specific endopeptidase using an ADVIA® 1650 instrument is plotted against the percentage of glycosylated hemoglobin present in the samples determined using the DCA® 2000 HbA1c assay.

[0013] FIG. 7 depicts a correlation slope in which the percentage of glycosylated hemoglobin determined to be present in human whole blood samples containing hemoglobin S and hemoglobin C that were reacted with an agglutinator reagent and 0.33 U/mL proline-specific endopeptidase using an ADVIA® 1650 instrument is plotted against the percentage of glycosylated hemoglobin present in the samples determined using the DCA® 2000 HbA1c assay.

[0014] FIG. 8 depicts a correlation slope in which the percentage of glycosylated hemoglobin determined to be present in human whole blood samples containing hemoglobin S and hemoglobin C that were reacted with an agglutinator reagent

and 0.43 U/mL proline-specific endopeptidase using an ADVIA® 1650 instrument is plotted against the percentage of glycosylated hemoglobin present in the samples determined using the DCA® 2000 HbA1c assay.

[0015] FIG. 9 depicts a correlation slope in which the percentage of glycosylated hemoglobin determined to be present in human whole blood samples containing hemoglobin S and hemoglobin C that were reacted with an agglutinator reagent and 0.54 U/mL proline-specific endopeptidase using an ADVIA® 1650 instrument is plotted against the percentage of glycosylated hemoglobin present in the samples determined using the DCA® 2000 HbA1c assay.

[0016] FIG. 10 depicts values of the correlation slopes illustrated in FIGS. 3 to 9 plotted **[text missing or illegible when filed]**

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0017] Particular aspects of the present invention relate to methods for detecting glycosylated hemoglobin present in human blood that are not affected by the variation in amino acid sequence that can exist in hemoglobin β chains. The methods detect all glycosylated hemoglobin in a sample, regardless of the form of the hemoglobin that has been glycosylated, and thus detect glycosylated hemoglobin A, hemoglobin S, and hemoglobin C.

[0018] Hemoglobin S and hemoglobin C contain a point mutation at position 6 of the human hemoglobin β chain. The glutamic acid residue at position six of the hemoglobin A β chain is replaced with a lysine residue in hemoglobin C and with a valine residue in hemoglobin S. The glycosylated amino terminal 18 amino acids of the human hemoglobin A, hemoglobin S, and hemoglobin C β chains are shown below:

HbA:
Glucose-val-his-leu-thr-pro-**glu**-glu-lys-ser-ala-
val-thr-ala-leu-try-gly-lys-val - - -

HbC:
Glucose-val-his-leu-thr-pro-**lys**-glu-lys-ser-ala-
val-thr-ala-leu-try-gly-lys-val - - -

HbS:
Glucose-val-his-leu-thr-pro-**val**-glu-lys-ser-ala-
val-thr-ala-leu-try-gly-lys-val - - -

[0019] Proline specific endopeptidase (PSE) selectively cleaves at the carboxy side of the proline residue at position 5 of the human hemoglobin β chain. Digestion of samples containing hemoglobin A, hemoglobin S, and hemoglobin C with proline-specific endopeptidase thus yields the same glycosylated pentapeptide for each of hemoglobin A, hemoglobin S, and hemoglobin C.

[0020] Certain embodiments of the present invention relate to methods that include digesting endopeptidase-treated human hemoglobin-containing samples with proline specific endopeptidase to liberate the glycosylated or unglycosylated amino-terminal pentapeptide of the human hemoglobin β chain. The level of glycosylated pentapeptide in the samples can then be quantitated to provide an indication of the amount of glycosylated hemoglobin present in the samples.

[0021] As used herein, the terms “detect,” “detecting,” and all variations thereof refer to any method used to quantita-

tively determine the presence of glycosylated human hemoglobin or of the amino-terminal pentapeptide of glycosylated human hemoglobin present in a sample regardless of the amount of the glycosylated human hemoglobin or of the amino-terminal pentapeptide of glycosylated human hemoglobin present in the sample and regardless of the form of the hemoglobin present in the sample from which the peptide

[0022] As used herein, the term “glycosylated human hemoglobin” refers to any form of human hemoglobin to which a glucose molecule has been bound to the amino terminus of the β -chain of the hemoglobin without the action of an enzyme. The term “glycosylated β -chain amino-terminal pentapeptide of human hemoglobin” refers to the amino-terminal pentapeptide of the β -chain of any form of human hemoglobin to which a glucose molecule has been bound to the amino-terminus of the pentapeptide without the action of an enzyme.

[0023] As used herein, the terms “contacting,” “contact,” and all variations thereof, refer to any means that directly or indirectly cause placement together of moieties or components, such that the moieties or components come into physical contact with each other. Contacting thus includes physical acts such as placing the moieties or components together in a container, combining the moieties or components, or mixing the moieties or components.

[0024] As used herein, the term “endopeptidase” refers to any enzyme that hydrolyzes a peptide bond in a peptide, polypeptide or protein.

[0025] As used herein, the term “acid endopeptidase” refers to any enzyme that hydrolyzes a peptide bond in a peptide, polypeptide or protein in an acidic environment.

[0026] As used herein, the terms “mixing,” “mix,” “adding,” and “add,” and all variations thereof, refer to any means that directly or indirectly cause placement together of moieties or components, such that the moieties or components come into close proximity to each other. The terms include acts such as placing the moieties or components together in a container, combining the moieties or components, contacting the moieties or components, or stirring, vortexing, or agitating the moieties or components together. The term “mixture” refers to moieties or components that have been placed together in close proximity.

[0027] Particular aspects of the invention relate to methods for detecting glycosylated human hemoglobin that comprise contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase, contacting the endopeptidase-treated sample with proline-specific endopeptidase, and detecting glycosylated β -chain amino-terminal pentapeptide of human hemoglobin present in the sample.

[0028] In preferred embodiments of the invention, the sample is human whole blood.

[0029] In certain embodiments of the invention, the percentage of glycosylated human hemoglobin in the sample is determined. In such methods, the concentration of glycosylated human hemoglobin in the sample is determined and the total hemoglobin concentration, which includes both glycosylated human hemoglobin in the sample is calculated by dividing the concentration of the glycosylated hemoglobin by the concentration of the total hemoglobin.

[0030] The total hemoglobin concentration in the sample can be determined using methods familiar to those skilled in the art, including, for example, an assay based on the conversion of all hemoglobin derivatives into alkaline hematin upon treatment with an alkaline solution of a nonionic detergent, as

described in Wolf, H. U., et al., *Clin Chim Acta*, 1984, 136, 95-104 and Zander R., et al., *Clin Chim Acta*, 1984, 136, 83-93, incorporated herein by reference in their entireties. Alkaline hematin has a defined absorption spectrum at 600 nm, and the hematin content can be measured by determining absorption at 600 nm.

[0031] Any endopeptidase can be used to initially digest the human hemoglobin present in a sample before digestion with proline-specific endopeptidase. The endopeptidase digestion can be performed manually or can be performed automatically on any chemistry system capable of sample dilution.

[0032] In particular embodiments of the invention, the endopeptidase is an acid endopeptidase. In preferred embodiments of the invention, the acid endopeptidase is pepsin, aspergillopepsin II, cathepsin D, saccharopepsin, mucorpepsin, chymosin, gastricsin, or physiolisin. In particularly preferred embodiments, the acid endopeptidase is pepsin. In certain aspects of the invention, the samples are digested with about 5 U/mL to about 10,000 U/mL pepsin. In preferred embodiments, the samples are digested with about 4,800 U/mL to about 8,600 U/mL pepsin. In particularly preferred embodiments, the samples are digested with about 6,000 U/mL to about 7,000 U/mL pepsin. In particular embodiments of the invention, the pepsin digestion is performed at a pH in the range of about 1.0 to about 5.0. In preferred embodiments of the invention, the pepsin digestion is performed at a pH in the range of about 2.0 to about 4.0. In particularly preferred embodiments of the invention, the pepsin digestion is performed at a pH in the range of about 2.3 to about 2.5.

[0033] In certain embodiments of the invention, following endopeptidase digestion, samples are digested with proline-specific endopeptidase. In particular embodiments, such samples are treated with about 0.1 U/mL to about 30 U/mL proline-specific endopeptidase. In preferred embodiments, such samples are treated with about 0.3 U/mL to about 5.0 U/mL proline-specific endopeptidase. In particularly preferred embodiments, such samples are treated with about 0.5 U/mL to about 0.8 U/mL proline-specific endopeptidase. In particular embodiments of the **[text missing or illegible when filed]** about 5.0 to about 9.0. In preferred embodiments of the invention, such proline-specific endopeptidase digestions are performed at a pH in the range of about 6.0 to about 8.0. In particularly preferred embodiments of the invention, such proline-specific endopeptidase digestions are performed at a pH in the range of about 6.9 to about 7.1.

[0034] The glycosylated β -chain amino-terminal pentapeptide of human hemoglobin liberated following endopeptidase and proline-specific endopeptidase digestion can be detected with any method, including, for example, methods that comprise the use of high performance liquid chromatography or that comprises the binding of at least one antibody, whether polyclonal or monoclonal, to the glycosylated pentapeptide.

[0035] In preferred embodiments of the invention, the glycosylated β -chain amino-terminal pentapeptide of human hemoglobin is detected with an agglutination inhibition immunoassay, as described, for example, in U.S. Pat. No. 4,847,209, incorporated herein by reference in its entirety. In particular examples of such assays, samples containing the glycosylated β -chain amino-terminal pentapeptide of human hemoglobin are mixed with an agglutinator reagent, such as, for example, glycosylated val-his-leu-thr-tyr-cys sexapeptide conjugated to polyaspartamide. Samples are also mixed with an antibody. In preferred embodiments of the invention, the antibody specifically binds to both the glycosylated β -chain amino-terminal pentapeptide of human hemoglobin and the agglutinator reagent.

In particular aspects of the invention, at least one antibody molecule is bound to one or more latex particles. Preferred antibodies include, for example, latex-coated mouse monoclonal anti-HbA1c antibody.

[0036] In such agglutination inhibition immunoassays, the β -chain amino-terminal glycosylated pentapeptide of human hemoglobin in a sample competes with the agglutinator reagent for antibody binding sites and slows the rate of agglutination, which occurs when the agglutinator reagent binds the latex-coated antibody. The more β -chain amino-terminal glycosylated pentapeptide of human hemoglobin present in the sample, the slower the rate of agglutination. The rate of agglutination thus provides an indication of the concentration of the β -chain amino-terminal glycosylated pentapeptide of human hemoglobin present in the sample.

[0037] The endopeptidase digestion, proline-specific endopeptidase digestion, and agglutination inhibition immunoassay can be performed in various ways. For example, in certain embodiments of the invention, the samples are first digested with an endopeptidase and the endopeptidase-treated samples are then reacted with proline-specific endopeptidase, followed by contacting the sample with an agglutinator reagent, followed by contacting the samples with an antibody. In other embodiments of the invention, the samples are first digested with an endopeptidase and the endopeptidase-treated samples are then contacted with a mixture of proline-specific endopeptidase and an agglutinator reagent, followed by contacting the samples with an antibody. In still further embodiments of the invention, the samples are first digested with an endopeptidase and the endopeptidase-treated samples are then contacted with an agglutinator reagent, followed by contacting the samples with proline-specific endopeptidase, followed by contacting the samples with an antibody.

[0038] Particular aspects of the invention thus relate to methods that comprise contacting samples with an endopeptidase and contacting the endopeptidase-treated samples with proline specific endopeptidase either simultaneously with, prior to, or following contacting the sample with an agglutinator reagent.

[0039] In preferred embodiments of the invention, the endopeptidase-treated sample is contacted with a mixture of proline specific endopeptidase and the agglutinator reagent. In particular examples of such embodiments, the mixture of proline specific endopeptidase and the agglutinator reagent comprises about 0.1 g/dL to about 5.0 g/dL bovine serum albumin and about 0.5 mmol/L to about 10.0 mmol/L ethylenediamine tetraacetic acid and has a pH in the range of about 6.0 to about 8.0. In preferred examples of such embodiments, the mixture of proline specific endopeptidase and the agglutinator reagent comprises about 1.0 g/dL to about 2.0 g/dL bovine serum albumin and about 1.0 mmol/L to about 5.0 mmol/L ethylenediamine tetraacetic acid and has a pH in the range of about 6.0 to about 8.0. In particularly preferred examples of such embodiments, the mixture of proline specific endopeptidase and the agglutinator reagent comprises about 1.4 g/dL to about 1.6 g/dL bovine serum albumin and about 2.9 mmol/L to about 3.1 mmol/L ethylenediamine tetraacetic acid and has a pH in the range of about 6.0 to about 8.0.

[0040] Particular embodiments of the invention relate to methods for detecting glycosylated human hemoglobin in which a sample is contacted with an endopeptidase and with an agglutinator reagent before contacting the sample with pro-

line-specific endopeptidase. If the sample in such methods is human whole blood, the sample may, in some instances, be initially diluted with, for example, saline.

[0041] Particular aspects of the invention thus relate to methods that comprise contacting a [text missing or illegible when filed] the sample with proline-specific endopeptidase, which is followed by contacting the sample with an antibody. Other embodiments of the invention relate to methods that comprise contacting a sample with a mixture of an endopeptidase and an agglutinator reagent, followed by contacting the sample with a mixture of proline-specific endopeptidase and an antibody. Further embodiments of the invention relate to methods that comprise contacting a sample with an agglutinator reagent followed by contacting the sample with pepsin, followed by contacting the sample with proline-specific endopeptidase, followed by contacting the sample with an antibody. Additional aspects of the invention relate to methods that comprise contacting a sample with an agglutinator reagent followed by contacting the sample with pepsin, followed by contacting the sample with a mixture of proline-specific endopeptidase and an antibody. Other aspects of the invention relate to methods that comprise contacting a sample with pepsin followed by contacting the sample with an agglutinator reagent, followed by contacting the sample with proline-specific endopeptidase, followed by contacting the sample with an antibody. Certain additional embodiments of the invention relate to methods that comprise contacting a sample with pepsin followed by contacting the sample with an agglutinator reagent, followed by contacting the sample with a mixture of proline-specific endopeptidase and an antibody.

[0042] Aspects of the invention thus relate to methods for detecting glycosylated human hemoglobin that comprise contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase either simultaneously with, prior to, or following contacting the sample with an agglutinator reagent, contacting the endopeptidase and agglutinator reagent-treated sample with proline-specific endopeptidase, and detecting glycosylated β -chain amino-terminal pentapeptide of human hemoglobin with an agglutination inhibition immunoassay. In preferred embodiments of such methods, the sample is contacted with a mixture of pepsin and the agglutinator reagent, which preferably comprises about 3 U/mL to about 100 U/mL pepsin and has a pH in the range of about 1.0 to about 4.0.

[0043] Further aspects of the invention relate to methods for detecting glycosylated human hemoglobin that comprise contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase either simultaneously with, prior to, or following contacting the sample with an agglutinator reagent, contacting the endopeptidase and agglutinator reagent-treated sample with proline-specific endopeptidase either simultaneously with or before contacting the sample with an antibody that specifically binds to both glycosylated β -chain amino-terminal pentapeptide of pentapeptide of human hemoglobin with an agglutination inhibition immunoassay. In preferred embodiments of such methods, the endopeptidase and agglutinator reagent-treated sample are contacted with a mixture of proline specific endopeptidase and the antibody, which preferably comprises about 2.0 U/mL to about 30.0 U/mL proline specific endopeptidase and has a pH in the range of about 7.0 to about 8.0.

[0044] The following examples are illustrative of certain embodiments of the invention and should not be considered to limit the scope of the invention.

Example 1

Digestion of Human Whole Blood Samples with Pepsin and Proline-Specific Endopeptidase

[0045] 7.5 μ L of DCA N (Normal control, DCA® 2000 Analyzer reagent kit (Siemens Medical Solutions Diagnostics)) or DCA AB (Abnormal control, DCA® 2000 Analyzer reagent kit (Siemens Medical Solutions Diagnostics)) were incubated at room temperature for 20 minutes with 150 μ L Sample Denaturant Reagent (ADVIA® HbA1c reagent kit (Siemens Medical Solutions Diagnostics)) containing 250 U/mL of pepsin. 150 μ L proline-specific endopeptidase (30 U/mL) in 0.1 mol/L phosphate buffer, pH 7.0, was added to half the pepsin-treated samples, and the proline-specific endopeptidase-treated samples were incubated for 30 minutes at room temperature. The remaining pepsin-treated samples were not treated with proline-specific endopeptidase, and 150 μ L 0.1 mol/L phosphate buffer, pH 7.0, was added to those samples.

[0046] All samples were then tested in an agglutination inhibition immunoassay on an ADVIA® 1650 instrument by adding the samples to a mixture of latex coated with mouse monoclonal anti-HbA1c antibody (ADVIA® HbA1c reagent kit, R1 (Siemens Medical Solutions Diagnostics)) followed by the addition of the β -chain amino-terminal glycosylated hexapeptide of human hemoglobin conjugated to polyaspartamide (agglutinator reagent, ADVIA® HbA1c reagent kit, R2 (Siemens Medical Solutions Diagnostics)). The β -chain amino-terminal glycosylated pentapeptide of human hemoglobin in the sample competes with the agglutinator reagent for antibody binding sites and slows the rate of agglutination, which occurs when the agglutinator reagent binds the latex-coated antibody. The more β -chain amino-terminal glycosylated pentapeptide of human hemoglobin in the sample, the slower the rate of agglutination. The reaction was monitored at 694 nm and the difference in agglutination rates between the treated samples and a saline blank was determined. The results of the experiments are listed in Table 1 below and indicate that after treatment with pepsin, addition of proline-specific endopeptidase results in higher inhibition of agglutination, demonstrating that the β -chain terminal glycosylated pentapeptide of hemoglobin is released.

TABLE 1

Sample	20 min Pepsin	20 min Pepsin + 30 min PSE (30 U/mL)
DCA N	-0.13856	-0.17681
DCA AB	-0.19191	-0.21345

Example 2

Formulation of a Proline-Specific Endopeptidase-Containing Agglutinator Reagent

[0047] Conditions for the stable formulation of a reagent containing the agglutinator used in Example 1 (β -chain amino-terminal glycosylated hexapeptide of human hemoglobin conjugated to polyaspartamide) and proline-specific endopeptidase at pH 7.0 were determined.

[0048] Solutions of the agglutinator (approximately 1.5 μ g/mL) containing 0.02 mol/L morpholino-propane-sulfonic acid (MOPS), 0.05% NaN₃, and 0.2% Tween-20, pH 7 were prepared either without ethylenediamine tetraacetic acid

(EDTA) and 0.4 U/mL proline-specific endopeptidase, with 1.1 mmol/L EDTA, or with both 1.1 mmol/L EDTA and 0.4 U/mL proline-specific endopeptidase. The ability of the agglutinator in the various formulations to cause agglutination of latex coated with mouse monoclonal anti-HbA1c antibody over a period of 14 days was then determined to assess the stability of the agglutinator over time. Samples were tested in an agglutination inhibition immunoassay on an ADVIA® 1650 instrument by first adding the samples to the agglutinator reagent described above (R1) and then adding latex coated with mouse monoclonal anti-HbA1c antibody (ADVIA® HbA1c reagent kit, (Siemens Medical Solutions Diagnostics)) to the samples. The β -chain amino-terminal glycosylated pentapeptide of human hemoglobin in the samples compete with the agglutinator reagent for antibody binding sites and slows the rate of agglutination, which occurs when the agglutinator reagent binds the latex-coated antibody. The more β -chain amino-terminal glycosylated pentapeptide of human hemoglobin in the samples, the slower the rate of agglutination. The reactions were monitored at 694 nm and the rates of agglutination were determined. FIG. 1 illustrates that the agglutinator was the most stable in the presence of EDTA only and was the least stable in the presence of both EDTA and proline-specific endopeptidase.

[0049] Additional solutions of the agglutinator (approximately 1.5 $\mu\text{g/mL}$) containing 0.4 U/mL proline-specific endopeptidase, 0.02 mol/L morpholino-propane-sulfonic acid (MOPS), 0.05% NaN_3 , and 0.2% Tween-20, pH 7 were prepared with both 1.1 mmol/L EDTA and 1% BSA or with only 1% BSA. The ability of the agglutinator in the various formulations to cause agglutination of latex coated with mouse monoclonal anti-HbA1c antibody over time was again determined. FIG. 2 illustrates that the agglutinator in the presence of proline-specific endopeptidase was more stable in solutions containing both bovine serum albumin (BSA) and EDTA than it was in solutions containing BSA only. The data provided in FIGS. 1 and 2 indicate that EDTA and BSA act synergistically to stabilize proline-specific endopeptidase-containing agglutinator reagent solutions.

Example 3

Determination of Pepsin Digestion Conditions

[0050] 2 μL samples of lyophilized human whole blood containing various concentrations of HbA1c (Whole Blood HbA1c Calibrators, Aalto Scientific) were manually digested with 148 μL of 250 U/mL pepsin (Sample Denaturant Reagent (ADVIA® HbA1c reagent kit (Siemens Medical Solutions Diagnostics)) for 10 minutes, were digested for nine seconds with approximately 6000 U/mL pepsin in a 0.02 mmol/L citrate, 0.2% Triton X100 pH 2.4 solution in an automated fashion, or were digested for ten minutes with approximately 6000 U/mL pepsin in a 0.02 mmol/L citrate, 0.2% Triton X100 pH 2.4 solution in an automated fashion. The samples were then assessed in an agglutination inhibition immunoassay on an ADVIA® 1650 instrument as described in Example 2 where R1 was the agglutinator reagent containing 0.4 U/mL proline-specific endopeptidase. The lack of change among the agglutination rates listed for the different denaturing conditions for each respective sample in Table 2 below indicates that 9 seconds is sufficient for the pepsin denaturant containing approximately 6000 U/mL to digest hemoglobin.

TABLE 2

Sample conc ($\mu\text{mol/L}$) HbA1c	Manual 10 min with sample denaturant ~250 U/mL pepsin	Automated 9 sec with ~6000 U/mL pepsin	Automated 10 min with ~6000 U/mL pepsin
Agglutination rate			
0.00	0.27170	0.27137	0.27137
2.37	0.11992	0.11749	0.11868
3.79	0.06581	0.06694	0.06621
4.75	0.04172	0.04162	0.04224
②	②	②	②

② indicates text missing or illegible when filed

Example 4

Pepsin and Proline-Specific Endopeptidase Digestion of Human Whole Blood Reduces Interference Caused by Hemoglobin S and Hemoglobin C When Calculating the Percentage of Glycosylated Hemoglobin: Proline-Specific Endopeptidase Digestion in the Presence of an Agglutinator Reagent

[0051] Human whole blood samples containing Hemoglobin S (HbS) or Hemoglobin C (HbC) were tested in an agglutination inhibition immunoassay on an ADVIA® 1650 instrument as described in Example 2 to determine the concentration of glycosylated hemoglobin in the samples. The endopeptidase reagent contained approximately 6000 U/mL pepsin in 0.02 mol/L citrate buffer, pH 2.4, 0.2% Triton X100. The agglutinator reagent contained a mixture of approximately 1.5 $\mu\text{g/mL}$ agglutinator (β -chain amino-terminal glycosylated hexapeptide of human hemoglobin conjugated to polyaspartamide) and increasing concentrations of proline-specific endopeptidase (0 U/mL, 0.1 U/mL, 0.2 U/mL, 0.33 U/mL, 0.43 U/mL and 0.54 U/mL) in a solution of 0.02 mol/L MOPS pH 7.0, 0.05% NaN_3 , 0.2% Tween-20, 3 mmol/L EDTA, and 1.5% BSA.

[0052] The total hemoglobin concentration, which includes both glycosylated and non-glycosylated hemoglobin, in the samples was determined using the ADVIA® Total Hemoglobin Reagent (ADVIA® HbA1c reagent kit (Siemens Medical Solutions Diagnostics)) in an assay based on the conversion of all hemoglobin derivatives into alkaline hematin upon treatment with an alkaline solution of a nonionic detergent. Samples were added to the Total Hemoglobin Reagent and hemoglobin species were converted into alkaline hematin, which has a defined absorption spectrum at 596 nm. The hematin content was measured by determining absorption at 596 nm.

[0053] The percentage of glycosylated hemoglobin present in each sample was determined by dividing the concentration of glycosylated hemoglobin calculated for each sample by the concentration of total hemoglobin determined for the sample.

[0054] For comparative purposes, the percentage of glycosylated hemoglobin present in human whole blood samples containing hemoglobin S and hemoglobin C was also determined using the DCA® 2000 HbA1c assay (DCA® 2000 Analyzer and reagent kit (Siemens Medical Solutions Diagnostics)). The DCA® 2000 assay is known to have no interference from the presence of hemoglobin C and hemoglobin S variants. The percentage of glycosylated hemoglobin present in the samples was also determined using a standard HbA1c assay performed using the ADVIA® 1650 HbA1c method

(Siemens Medical Solutions Diagnostics). The parameters listed in the Table 3 below were used on an ADVIA® 1650 instrument to evaluate the effect of proline-specific endopeptidase on hemoglobin variant interference. R1 was a mixture of the agglutinator (β -chain amino-terminal glycosylated sexapeptide of human hemoglobin conjugated to polyaspartamide) and 0.0-0.54 U/mL proline-specific endopeptidase in a solution of 0.02 mol/L MOPS pH 7.0, 0.05% NaN_3 , 0.2% Tween-20, 3.0 mmol/L EDTA, and 1.5% BSA. R2 was latex coated with mouse monoclonal anti-HbA1c antibody (ADVIA® HbA1c reagent kit, (Siemens Medical Solutions Diagnostics)).

TABLE 3

	Volume (μL)
R1	76
R2	76
Sample	3.2
Pretreatment	
Dilution	Special
Pepsin Reagent	148
Sample	2
Dil. Position	CTT
Assay type	2PA
m	56
n	72

TABLE 3-continued

	Volume (μL)
1	0
Wavelength	694 nm
Calc. method	MSTD
Curve fit	Log-Logit 3

The results of the experiments are presented in Table 4 below. "NV" in the table indicates that a value was not obtained at that data point, and ">>>>" indicates that the value was too high for the instrument to measure. A "C" following the numerical designations in column 1 of the table indicates that the sample contains hemoglobin C, and an "S" following the numerical designations in column 1 indicates that the sample contains hemoglobin S. The results obtained with the HbA1c assay performed using the ADVIA® 1650 HbA1c method are greatly affected by the presence of hemoglobin S and hemoglobin C in the samples as compared to the results obtained with the DCA® 2000 HbA1c assay. Comparison of the results of experiments performed using differing proline-specific endopeptidase concentrations with the results of experiments performed using the DCA® 2000 HbA1c assay and using the ADVIA® 1650 instrument illustrates that interference in measurement of glycosylated hemoglobin caused by hemoglobin S and hemoglobin C is eliminated at a proline-specific endopeptidase concentration of 0.54 U/mL.

TABLE 4

Sample	DCA	0.0	0.1	0.2	0.33	0.43	0.54	ADVIA 1650
		U/mL PSE	U/mL PSE	U/mL PSE	U/mL PSE	U/mL PSE	U/mL PSE	
6C	8.7	11.97	10.56	10.09	9.44	8.97	8.72	11.88
14C	6.8	8.26	7.74	7.09	6.93	6.95	6.56	8.07
18C	7.4	8.63	8.44	8.50	8.40	7.86	7.94	7.97
42C	6.2	7.61	7.02	6.65	6.47	6.37	6.10	7.67
46C	6	6.90	6.55	6.39	6.12	6.10	5.83	6.90
47C	6.5	8.03	7.10	6.92	6.59	6.70	6.33	7.79
64C	9.3	12.67	11.44	10.84	10.29	9.85	9.53	15.07
97C	5.5	8.37	7.91	7.46	7.17	6.83	6.62	8.44
126C	8.6	12.47	11.58	10.92	10.20	9.42	9.42	13.08
187S	6.8	7.42	7.02	6.73	6.62	6.77	6.74	7.92
188S	6.1	7.41	6.82	6.46	6.43	6.17	6.12	7.41
191C	6	7.76	7.34	6.80	6.72	6.39	6.12	7.83
192S	6.5	7.69	7.17	6.81	6.58	6.29	6.08	7.75
213S	6.4	7.44	6.93	6.52	6.26	6.09	5.96	7.62
214S	5.6	7.18	6.43	6.16	5.87	5.68	5.64	7.07
215S	6.1	7.87	7.34	NV	6.63	6.55	6.29	7.90
221S	6.8	8.11	7.78	7.63	7.09	7.20	6.95	8.39
222C	7.2	10.69	9.88	9.05	8.46	7.93	7.88	10.69
236C	5.9	8.02	7.47	7.23	6.70	6.50	6.36	8.09
239S	5.6	6.80	6.59	6.07	6.18	5.74	5.70	6.85
244S	5.6	6.48	6.19	5.92	5.70	5.68	5.55	6.73
245C	6.6	8.46	7.77	7.82	7.44	7.28	7.16	8.51
246S	8.2	11.22	9.76	9.48	9.00	8.42	8.23	10.75
248S	13	19.61	17.29	16.00	14.63	12.98	13.11	>>>>
251C	5.9	7.22	6.91	6.62	6.46	6.31	6.07	7.37
252S	6.2	7.41	6.91	6.56	6.46	6.26	6.26	7.47
253C	6.3	8.72	8.43	7.59	7.24	7.07	6.79	8.76

[0055] The percentage of glycosylated hemoglobin present in the samples, as calculated from experiments performed with an ADVIA® 1650 instrument using the differing proline-specific endopeptidase concentrations (Table 4, columns 3 to 8) and performed using the ADVIA® 1650 HbA1c method (Table 4, column 9), were plotted against the glycosylated hemoglobin percentages calculated using the DCA® 2000 HbA1c assay (Table 4, column 2) to obtain correlation slopes for the glycosylated hemoglobin percentages calculated at each proline-specific endopeptidase concentration and for the percentages calculated using the ADVIA® 1650 HbA1c method. The results are shown in FIGS. 3 to 9, which indicate that as the proline-specific endopeptidase concentration increased, interference in calculating the percentage of glycosylated hemoglobin present in the samples caused by hemoglobin S and hemoglobin C decreased until it was eliminated.

[0056] The values of the correlation slopes determined as described in the preceding paragraph and illustrated in FIGS. 3 to 9 were plotted against the proline-specific endopeptidase concentration (FIG. 10), demonstrating that digestion of human whole blood samples containing hemoglobin S and hemoglobin C with pepsin followed by digestion with at least 0.43 U/mL proline-specific endopeptidase in the presence of an agglutinator reagent eliminates interference caused by hemoglobin S and hemoglobin C when calculating the percentage of glycosylated hemoglobin present in the samples.

Example 5

Pepsin and Proline-Specific Endopeptidase Digestion of Human Whole Blood Reduces Interference Caused by Hemoglobin S and Hemoglobin C When Calculating the Percentage of Glycosylated Hemoglobin: Pepsin Digestion in the Presence of an Agglutinator Reagent

[0057] Human whole blood samples containing hemoglobin S and hemoglobin C were diluted with saline solution on an ADVIA 1650 instrument using the parameters listed in table 5.

TABLE 5

	Volume (µL)
R1	76
R2	76
Sample	3.2
Pretreatment	
Dilution	Special
Saline	148
Sample	2
Dil. Position	CTT
Assay type	2PA
m	56
n	72
l	0
Wavelength	694 nm
Calc. method	MSTD
Curve fit	Log-Logit 3

The saline-diluted samples were then mixed with an agglutinator reagent containing approximately 1.5 µg agglutinator (β-chain amino-terminal glycosylated sexapeptide of human hemoglobin conjugated to polyaspartamide) and 6 U/mL pepsin in 0.02 mol/L citrate buffer, pH 2.4, and the mixture was incubated for five minutes. Solutions of latex coated with mouse monoclonal anti-HbA1c antibody (ADVIA® HbA1c

reagent kit, (Siemens Medical Solutions Diagnostics)) containing increasing concentrations of proline-specific endopeptidase (0.0, 1.0, 2.0, 3.0, 4.0, or 5.0 U/mL) (pH 7) were then added to the agglutinator reagent/pepsin solution and the mixture was incubated for five minutes. Agglutination rates at 694 nm were determined using an ADVIA® 1650 instrument, and the agglutination rates were used to calculate the concentration of glycosylated hemoglobin S or hemoglobin C in the samples.

[0058] For comparative purposes, the percentage of glycosylated hemoglobin present in the samples was also determined using the DCA® 2000 HbA1c assay (DCA 2000® Analyzer and reagent kit (Siemens Medical Solutions Diagnostics)).

[0059] The total hemoglobin concentration in the samples was determined according to the procedures described in Example 4, and the percentage of glycosylated hemoglobin present in each sample was also determined as described in Example 4. The results of the experiments are presented in Table 6 below and indicate that digestion of human whole blood samples with pepsin in the presence of an agglutinator reagent followed by digestion with proline-specific endopeptidase significantly reduces interference caused by hemoglobin S and hemoglobin C present in the samples when calculating the percentage of glycosylated hemoglobin present in the samples.

TABLE 6

U/mL PSE	0	1	2	3	4	5	DCA
Sam- ple ID	U/mL	U/mL	U/mL	U/mL	U/mL	U/mL	
	% Glycosylated Hb						
185S	10.36	10.95	9.71	8.89	8.65	8.55	10.1
180C	6.25	5.93	5.54	5.29	5.14	5.10	5.6
22C	13.72	11.33	10.72	9.42	9.00	8.61	9.12
172S	12.22	11.03	10.43	9.86	9.53	9.00	10.6

[0060] The entire disclosure of each patent, patent application, and publication cited or described in this document is hereby incorporated herein by reference.

We claim:

1. A method for detecting glycosylated human hemoglobin comprising:
 - contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase;
 - contacting the endopeptidase-treated sample with proline-specific endopeptidase; and
 - detecting glycosylated β-chain amino-terminal pentapeptide of human hemoglobin.
2. The method of claim 1 wherein the sample is human whole blood.
3. The method of claim 1 comprising determining the percentage of glycosylated human hemoglobin in the sample.
4. The method of claim 1 wherein the endopeptidase is an acid endopeptidase selected from the group consisting of pepsin, aspergillopepsin II, cathepsin D, saccharopepsin, mucorpepsin, chymosin, gastricsin, and physisirolisin.
5. The method of claim 4 wherein the acid endopeptidase is pepsin.
6. The method of claim 5 comprising contacting the sample with about 5 U/mL to about 10,000 U/mL pepsin at a pH in the range of about 1.0 to about 5.0.

7. The method of claim 1 comprising contacting the endopeptidase-treated sample with about 0.1 U/mL to about 30 U/mL proline specific endopeptidase at a pH in the range of about 5.0 to about 9.0.

8. The method of claim 1 comprising detecting the glycosylated β -chain amino-terminal pentapeptide of human hemoglobin with a method that comprises the use of high performance liquid chromatography or that comprises the binding of at least one antibody to the glycosylated pentapeptide.

9. The method of claim 1 comprising detecting the glycosylated β -chain amino-terminal pentapeptide of human hemoglobin with an agglutination inhibition immunoassay **[text missing or illegible when filed]**

10. The method of claim 9 wherein the agglutinator reagent used in the agglutination inhibition immunoassay is a glycosylated val-his-leu-thr-tyr-cys sexapeptide conjugated to polyaspartamide.

11. The method of claim 9 comprising contacting the endopeptidase-treated sample with proline specific endopeptidase either simultaneously with, prior to, or following contacting the sample with an agglutinator reagent.

12. The method of claim 11 comprising contacting the endopeptidase-treated sample with a mixture of proline specific endopeptidase and the agglutinator reagent.

13. The method of claim 12 wherein the mixture of proline specific endopeptidase and the agglutinator reagent comprises about 0.1 g/dL to about 5.0 g/dL bovine serum albumin and about 0.5 mmol/L to about 10.0 mmol/L ethylenediamine tetraacetic acid and has a pH in the range of about 6.0 to about 8.0.

14. The method of claim 11 further comprising contacting the endopeptidase, proline specific endopeptidase, and agglutinator reagent-treated sample with an antibody that specifically binds to both glycosylated β -chain amino-terminal pentapeptide of human hemoglobin and the agglutinator reagent.

15. The method of claim 14 wherein at least one antibody molecule is bound to one or more latex particles.

16. A method for detecting glycosylated human hemoglobin comprising:

contacting a sample to be tested for glycosylated human hemoglobin with an endopeptidase either simultaneously with, prior to, or following contacting the sample with an agglutinator reagent;

contacting the endopeptidase and agglutinator reagent-treated sample with proline-specific endopeptidase; and detecting glycosylated β -chain amino-terminal pentapeptide of human hemoglobin with an agglutination inhibition immunoassay.

17. The method of claim 16 wherein the endopeptidase is an acid endopeptidase selected from the group consisting of pepsin, aspergillopepsin II, cathepsin D, saccharopepsin, mucorpepsin, chymosin, gastricsin, or physiolisin.

18. The method of claim 17 wherein the acid endopeptidase is pepsin.

19. The method of claim 18 comprising contacting the sample with a mixture of pepsin and the agglutinator reagent.

20. The method of claim 19 wherein the mixture of pepsin and the agglutinator reagent comprises about 3 U/mL to about 100 U/mL pepsin and has a pH in the range of about 1.0 to about 4.0.

21. The method of claim 16 further comprising contacting the endopeptidase and agglutinator reagent-treated sample with proline specific endopeptidase either simultaneously with or before contacting the sample with an antibody that specifically binds to both glycosylated β -chain amino-terminal pentapeptide of human hemoglobin and the agglutinator reagent.

22. The method of claim 21 comprising contacting the endopeptidase and agglutinator reagent-treated sample with a mixture of proline specific endopeptidase and the antibody.

23. The method of claim 22 wherein the mixture comprises about 2.0 U/mL to about 30.0 U/mL proline specific endopeptidase and has a pH in the range of about 7.0 to about 8.0.

24. The method of claim 21 wherein at least one antibody molecule is bound to one or more latex particles.

* * * * *

专利名称(译)	检测糖化血红蛋白的方法		
公开(公告)号	US20100273181A1	公开(公告)日	2010-10-28
申请号	US12/743615	申请日	2008-11-18
[标]申请(专利权)人(译)	西门子医疗保健诊断公司		
申请(专利权)人(译)	西门子医疗诊断INC.		
[标]发明人	CHAPOTEAU EDDY EDWARDS RICHARD SWIRSKI CHESTER ZAZULAK WOLODYMYR		
发明人	CHAPOTEAU, EDDY EDWARDS, RICHARD SWIRSKI, CHESTER ZAZULAK, WOLODYMYR		
IPC分类号	C12Q1/37 G01N33/53 G01N33/546		
CPC分类号	C12Q1/37 G01N33/53 G01N33/723		
优先权	60/989210 2007-11-20 US		
其他公开文献	US8715942		
外部链接	Espacenet USPTO		

摘要(译)

本发明的具体方面涉及用于检测例如人全血中的糖化血红蛋白的方法，所述方法不受可存在于血红蛋白β链中的氨基酸序列变化的影响。该方法检测样品中的所有糖化血红蛋白，无论已经糖化的血红蛋白的形式如何，因此检测糖化的人血红蛋白A，血红蛋白S和血红蛋白C。




Figure 1